ALLOGENE THERAPEUTICS ($ALLO) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.28 per share, beating estimates of -$0.34 by $0.06. The company also reported revenue of $0, missing estimates of $14,280 by $-14,280.
You can see Quiver Quantitative's $ALLO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALLOGENE THERAPEUTICS Insider Trading Activity
ALLOGENE THERAPEUTICS insiders have traded $ALLO stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ALLO stock by insiders over the last 6 months:
- ZACHARY ROBERTS (EVP of R&D) has made 0 purchases and 2 sales selling 46,031 shares for an estimated $80,428.
- DAVID D CHANG (President and CEO) sold 46,003 shares for an estimated $77,285
- DEBORAH M. MESSEMER has made 0 purchases and 2 sales selling 22,449 shares for an estimated $52,267.
- TIMOTHY L. MOORE (Chief Technical Officer) sold 14,746 shares for an estimated $25,215
- FRANZ B HUMER sold 9,221 shares for an estimated $19,917
- EARL MARTIN DOUGLAS (SVP, General Counsel) sold 6,404 shares for an estimated $10,950
- GEOFFREY M. PARKER (CHIEF FINANCIAL OFFICER) sold 4,361 shares for an estimated $7,544
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALLOGENE THERAPEUTICS Hedge Fund Activity
We have seen 81 institutional investors add shares of ALLOGENE THERAPEUTICS stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 6,254,961 shares (-20.8%) from their portfolio in Q4 2024, for an estimated $13,323,066
- LYNX1 CAPITAL MANAGEMENT LP added 4,672,349 shares (+75.3%) to their portfolio in Q4 2024, for an estimated $9,952,103
- BOXER CAPITAL, LLC removed 3,850,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $10,780,000
- PERCEPTIVE ADVISORS LLC removed 2,725,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $5,804,250
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 1,634,838 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,482,204
- PATIENT SQUARE CAPITAL LP added 1,489,909 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,173,506
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 878,955 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,461,074
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
